such as aiming for greater weight loss than Wegovy or the same as Zepbound. Martin Holst Lange, Novo Nordisk’s executive vice president for development, said Novo was “encouraged” by the data.

The experimental drug puts semaglutide, the ingredient in Ozempic and the weight-loss drug Wegovy, together with a medicine called cagrilintide to make the combination Novo Nordisk calls CagriSema.

Within Novo Nordisk's comprehensive business update to investors, attention latched onto early data for an oral obesity therapy that outperformed the company’s big-selling GLP-1 agonist Wegovy ...

CagriSema, a drug that Novo Nordisk had hoped would become its ... the active ingredient in its blockbuster Wegovy, with cagrilintide, a dual approach that suppresses the appetite and manages ...

Novo Nordisk's sales of blockbuster obesity drug Wegovy grew by a massive 79% in the third quarter, in a relief to investors after disappointing results three months ago. GLP-1 agonist Wegovy ...

Eli Lilly's Zepbound and Novo Nordisk's Wegovy are the two most prominent brands in this area, which is projected to grow by leaps and bounds in the coming years. Which of these companies will ...

According to leading data and analytics company GlobalData, Eli Lilly’s Zepbound (tirzepatide) is poised to surpass Novo Nordisk’s Wegovy (semaglutide), despite expectations for continued ...

Novo Nordisk, the maker of perhaps the most sought-after prescription drugs in the world, says Ozempic and Wegovy are now being shipped regularly to wholesalers. After a year where products were ...

Eli Lilly's Mounjaro has patients achieving up to 21% weight loss in the SURMOUNT-1 trial, which is significantly higher than the 15% that Novo Nordisk's Wegovy has achieved in comparable trials.

A Scandinavian economic behemoth, Novo Nordisk is the highest-valued company in Europe at over $500 billion, which exceeds Denmark’s entire GDP. Ironically, Ozempic and Wegovy, as with many of ...

Novo Nordisk also boasted a 55.6% share of the GLP-1 drug space, compared to 54.4% as of August 2023. The company's most famous brands, Wegovy and Ozempic, are both GLP-1s. They have helped Novo ...